…
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Income before tax | 6201.00M | 4359.00M | 3789.00M | 4630.00M | 1928.00M |
| Minority interest | -337.00M | -186.00M | -158.00M | 162.00M | -173.00M |
| Net income | 4762.00M | 3295.00M | 3002.00M | 3560.00M | 1114.00M |
| Selling general administrative | 8096.00M | 8507.00M | 6910.00M | 15552.00M | 21074.00M |
| Selling and marketing expenses | 8096.00M | - | 1100.00M | -7776.00M | -10537.00M |
| Gross profit | 14550.00M | 12485.00M | 12202.00M | 12358.00M | 13130.00M |
| Reconciled depreciation | 729.00M | 636.00M | 635.00M | 608.00M | 760.00M |
| Ebit | 6448.00M | 4615.00M | 4032.00M | 4381.00M | 2852.00M |
| Ebitda | 7177.00M | 5251.00M | 4667.00M | 5687.00M | 3612.00M |
| Depreciation and amortization | 729.00M | 636.00M | 635.00M | 1306.00M | 760.00M |
| Non operating income net other | - | - | - | 497.00M | 68.00M |
| Operating income | 6454.00M | 4372.00M | 3927.00M | 4381.00M | 2852.00M |
| Other operating expenses | 396976.00M | 354679.00M | 305024.00M | 272129.00M | 261373.00M |
| Interest expense | 247.00M | 256.00M | 243.00M | 248.00M | 178.00M |
| Tax provision | 1102.00M | 878.00M | 629.00M | 905.00M | 636.00M |
| Interest income | 179.00M | 173.00M | 118.00M | 248.00M | 10.00M |
| Net interest income | -68.00M | -92.00M | -134.00M | -248.00M | -178.00M |
| Extraordinary items | - | 0.00M | 0.00M | -3.00M | -5.00M |
| Non recurring | - | - | - | -8.00M | 274.00M |
| Income tax expense | 1102.00M | 878.00M | 629.00M | 905.00M | 636.00M |
| Total revenue | 403430.00M | 359051.00M | 308951.00M | 276711.00M | 263966.00M |
| Total operating expenses | 8096.00M | 8113.00M | 8275.00M | 7776.00M | 10537.00M |
| Cost of revenue | 388880.00M | 346566.00M | 296749.00M | 264353.00M | 250836.00M |
| Total other income expense net | -253.00M | -13.00M | -138.00M | 249.00M | -924.00M |
| Discontinued operations | - | - | - | -3.00M | -5.00M |
| Net income from continuing ops | 5099.00M | 3481.00M | 3160.00M | 3725.00M | 1292.00M |
| Net income applicable to common shares | - | 3295.00M | 3002.00M | 3560.00M | 1114.00M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Total assets | 82323.00M | 75140.00M | 67443.00M | 62320.00M | 63298.00M |
| Intangible assets | 4079.00M | 1464.00M | 2110.00M | 2277.00M | 2059.00M |
| Other current assets | 1043.00M | 1063.00M | 626.00M | 496.00M | 5414.00M |
| Total liab | 83157.00M | 76834.00M | 69042.00M | 63810.00M | 65090.00M |
| Total stockholder equity | -2172.00M | -1694.00M | -1599.00M | -1857.00M | -2272.00M |
| Deferred long term liab | - | - | - | 1387.00M | 1418.00M |
| Other current liab | 5490.00M | 4825.00M | 4915.00M | 4200.00M | 9284.00M |
| Common stock | 3.00M | 3.00M | 3.00M | 3.00M | 2.00M |
| Capital stock | 3.00M | 3.00M | 3.00M | 3.00M | 2.00M |
| Retained earnings | 22291.00M | 17921.00M | 14978.00M | 12295.00M | 9030.00M |
| Other liab | - | - | - | 9808.00M | 10142.00M |
| Good will | 11316.00M | 10022.00M | 10132.00M | 9947.00M | 9451.00M |
| Other assets | - | 3869.00M | 2946.00M | 1755.00M | 1251.00M |
| Cash | 3975.00M | 5691.00M | 4583.00M | 4678.00M | 3532.00M |
| Cash and equivalents | - | 5691.00M | 4583.00M | 4678.00M | 3532.00M |
| Total current liabilities | 67017.00M | 61604.00M | 52357.00M | 47957.00M | 48466.00M |
| Current deferred revenue | - | - | 1.00M | - | - |
| Net debt | 4639.00M | 1699.00M | 2807.00M | 2617.00M | 4010.00M |
| Short term debt | 1554.00M | 1449.00M | 345.00M | 1267.00M | 1096.00M |
| Short long term debt | 1267.00M | 1191.00M | 50.00M | 968.00M | 799.00M |
| Short long term debt total | 8614.00M | 7390.00M | 7390.00M | 7295.00M | 7542.00M |
| Other stockholder equity | -23013.00M | -19066.00M | -16071.00M | -13250.00M | -9770.00M |
| Property plant equipment | - | 4284.00M | 4045.00M | 2177.00M | 2092.00M |
| Total current assets | 57210.00M | 55398.00M | 47970.00M | 44292.00M | 46231.00M |
| Net tangible assets | - | - | - | -12679.00M | -12416.00M |
| Net receivables | 27985.00M | 25643.00M | 21622.00M | 19410.00M | 18583.00M |
| Long term debt | 5259.00M | 4463.00M | 5579.00M | 4626.00M | 5080.00M |
| Inventory | 24207.00M | 23001.00M | 21139.00M | 19691.00M | 18702.00M |
| Accounts payable | 59973.00M | 55330.00M | 47097.00M | 42490.00M | 38086.00M |
| Noncontrolling interest in consolidated entity | - | - | - | 367.00M | 480.00M |
| Accumulated other comprehensive income | -1453.00M | -932.00M | -881.00M | -905.00M | -1534.00M |
| Common stock total equity | - | - | - | 3.00M | 2.00M |
| Retained earnings total equity | - | - | - | 12295.00M | 9030.00M |
| Treasury stock | - | - | - | - | -17045.00M |
| Non currrent assets other | 4725.00M | 3972.00M | 2838.00M | 1992.00M | 1917.00M |
| Non current assets total | 25113.00M | 19742.00M | 19473.00M | 18028.00M | 17067.00M |
| Capital lease obligations | 2088.00M | 1736.00M | 1761.00M | 1701.00M | 1663.00M |
| Long term debt total | - | 5941.00M | 7045.00M | 4626.00M | 5080.00M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Investments | - | -733.00M | -1072.00M | -542.00M | -89.00M |
| Change to liabilities | - | - | - | 4151.00M | 3045.00M |
| Total cashflows from investing activities | -3432.00M | -733.00M | -1072.00M | -542.00M | -89.00M |
| Net borrowings | 783.00M | -21.00M | 56.00M | -277.00M | -1334.00M |
| Total cash from financing activities | -4631.00M | -3965.00M | -3342.00M | -4368.00M | -6321.00M |
| Change to operating activities | - | - | - | -1370.00M | 49.00M |
| Net income | 4762.00M | 3481.00M | 3160.00M | 3722.00M | 1287.00M |
| Change in cash | -1981.00M | 1371.00M | -94.00M | 743.00M | -2461.00M |
| Begin period cash flow | 5956.00M | 4585.00M | 4679.00M | 3935.00M | 6396.00M |
| End period cash flow | 3975.00M | 5956.00M | 4583.00M | 4678.00M | 3935.00M |
| Total cash from operating activities | 6155.00M | 6085.00M | 4314.00M | 5159.00M | 4434.00M |
| Issuance of capital stock | 89.00M | 101.00M | 116.00M | 163.00M | 220.00M |
| Depreciation | 729.00M | 636.00M | 635.00M | 608.00M | 760.00M |
| Other cashflows from investing activities | -101.00M | -351.00M | -416.00M | -152.00M | 299.00M |
| Dividends paid | 381.00M | 345.00M | 314.00M | -292.00M | -277.00M |
| Change to inventory | -1082.00M | -2270.00M | -1294.00M | -1259.00M | -1169.00M |
| Change to account receivables | -1999.00M | -3935.00M | -2954.00M | -1082.00M | -1843.00M |
| Sale purchase of stock | -4750.00M | -3146.00M | -3025.00M | -3638.00M | -3516.00M |
| Other cashflows from financing activities | -372.00M | -554.00M | -175.00M | 9123.00M | 10092.00M |
| Change to netincome | - | - | - | 140.00M | 2064.00M |
| Capital expenditures | 745.00M | 859.00M | 687.00M | 558.00M | 535.00M |
| Change receivables | - | - | - | -1082.00M | -1843.00M |
| Cash flows other operating | - | - | - | -1121.00M | 290.00M |
| Cash and cash equivalents changes | - | - | - | 249.00M | -1976.00M |
| Change in working capital | 162.00M | 1155.00M | -64.00M | 384.00M | 82.00M |
| Stock based compensation | - | - | 182.00M | - | - |
| Other non cash items | 272.00M | 923.00M | 1186.00M | 465.00M | 2271.00M |
| Free cash flow | 5410.00M | 5226.00M | 3627.00M | 4601.00M | 3899.00M |
Sector: Healthcare Industry: Medical Distribution
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MCK McKesson Corporation |
35.22 3.52% |
1034.84 | 24.45 | 20.41 | 0.26 | 5.04 | 0.27 | 15.03 |
| COR Cencora Inc. |
13.60 3.99% |
354.10 | 24.22 | 16.39 | 0.19 | 20.41 | 0.21 | 13.72 |
| CAH Cardinal Health Inc |
5.53 2.18% |
258.46 | 29.48 | 17.92 | 0.20 | 16.07 | 0.22 | 15.67 |
| HSIC Henry Schein Inc |
- -% |
88.24 | 25.89 | 15.08 | 0.72 | 3.14 | 1.00 | 13.43 |
| SHTDY SINOPHARM GROUP CO LTD ADR |
- -% |
10.58 | 6.18 | 7.49 | 0.01 | 0.76 | 0.03 | 0.72 |
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
6555 State Highway 161, Irving, TX, United States, 75039
972 446 4800
41600
| Name | Title | Year Born |
|---|---|---|
| Mr. Brian S. Tyler Ph.D. | CEO & Director | 1967 |
| Mr. Britt J. Vitalone | Exec. VP & CFO | 1969 |
| Ms. Nancy Avila | Exec. VP, Chief Information Officer & CTO | 1967 |
| Ms. Lori A. Schechter J.D. | Exec. VP, Chief Legal Officer & Gen. Counsel | 1962 |
| Mr. Napoleon B. Rutledge Jr. | Sr. VP, Controller & Chief Accounting Officer | 1972 |
| Ms. Holly Weiss | Sr. VP of Investor Relations | NA |
| Mr. Pete Slone | Sr. VP of Corp. Public Affairs | NA |
| Ms. LeAnn B. Smith | Exec. VP & Chief HR Officer | NA |
| Mr. Kirk Kaminsky | Pres of The US Pharmaceutical & Specialty Solutions Bus. | NA |
| Paul A. Smith | Sr. VP of Taxes | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.